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Summary
 
The three-dimensional structure of the complex between a T cell receptor (TCR) 
 
b
 
 chain
(mouse V
 
b
 
8.2J
 
b
 
2.1C
 
b
 
1) and the superantigen (SAG) staphylococcal enterotoxin C3 (SEC3)
has been recently determined to 3.5 Å resolution. To evaluate the actual contribution of indi-
vidual SAG residues to stabilizing the 
 
b
 
–SEC3 complex, as well as to investigate the relation-
ship between the affinity of SAGs for TCR and MHC and their ability to activate T cells, we
measured the binding of a set of SEC3 and staphylococcal enterotoxin B (SEB) mutants to sol-
uble recombinant TCR 
 
b
 
 chain and to the human MHC class II molecule HLA-DR1. Affini-
ties were determined by sedimentation equilibrium and/or surface plasmon detection, while
mitogenic potency was assessed using T cells from rearrangement-deficient TCR transgenic
mice. We show that there is a clear and simple relationship between the affinity of SAGs for
the TCR and their biological activity: the tighter the binding of a particular mutant of SEC3 or
SEB to the TCR 
 
b
 
 chain, the greater its ability to stimulate T cells. We also find that there is
an interplay between TCR–SAG and SAG–MHC interactions in determining mitogenic po-
tency, such that a small increase in the affinity of a SAG for MHC can overcome a large de-
crease in the SAG’s affinity for the TCR. Finally, we observe that those SEC3 residues that
make the greatest energetic contribution to stabilizing the 
 
b
 
–SEC3 complex (“hot spot” resi-
dues) are strictly conserved among enterotoxins reactive with mouse V
 
b
 
8.2, thereby providing
a basis for understanding why SAGs having other residues at these positions show different V
 
b
 
-
binding specificities.
 
S
 
uperantigens (SAGs)
 
1
 
 are a class of disease-causing and
immunostimulatory proteins of bacterial or viral origin.
In addition to causing toxic shock syndrome and food poi-
soning (1, 2), SAGs have been implicated in a number of
autoimmune disorders, including diabetes mellitus (3),
multiple sclerosis (4), and rheumatoid arthritis (5), through
the activation of T cells specific for self-antigens. SAGs are
able to recognize particular elements on the V
 
b
 
 domain of
TCRs, largely irrespective of their peptide–MHC specific-
ity, leading to stimulation of a disproportionally large frac-
tion of the T cell population. The activated T cells release
massive amounts of cytokines such as IL-2 and tumor ne-
crosis factor, contributing to the symptoms caused by
SAGs.
The structurally and immunologically best characterized
group of SAGs are the 
 
Staphylococcus aureus
 
 enterotoxins,
which are mainly associated with food poisoning and toxic
shock syndrome (1, 2). The three-dimensional structure of
the complex between staphylococcal enterotoxin C3
 
1
 
Abbreviations used in this paper:
 
 HA, hemaglutinin peptide; HBS, Hepes-
buffered saline; 
 
K
 
d
 
, dissociation constant; RU, resonance unit; SAG, super-
antigen; SEA, staphylococcal enterotoxin A; SEB, staphylococcal enterotoxin
B; SEC, staphylococcal enterotoxin C; SED, staphylococcal enterotoxin
D; SEE, staphylococcal enterotoxin E; SPEA, streptococcal pyrogenic exo-
toxin A.
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Superantigen Binding to TCR-
 
b
 
 Chain and MHC
 
(SEC3) and the 
 
b
 
 chain (V
 
b
 
8.2J
 
b
 
2.1.C
 
b
 
1) of a mouse
TCR (designated 14.3.d) specific for a peptide of influenza
virus hemagglutinin (HA 110–120) in the context of I-E
 
d
 
shows that CDR2 of the 
 
b
 
 chain, and to lesser extents
CDR1 and the fourth hypervariable region (HV4), bind in
a cleft between the small and large domains of the SAG (6).
The structure of the TCR 
 
b
 
–SEC3 complex agrees well
with mutational and genetic studies implicating residues in
V
 
b
 
 CDR1, CDR2, and HV4 in SAG recognition (2, 7).
In addition, mutagenesis of SAGs has revealed that the
stimulatory activity of these molecules is affected when res-
idues at the TCR binding site are altered (8). T cell stimu-
lation by SAGs is generally thought to require simultaneous
binding to MHC class II molecules on APCs and the V
 
b
 
element on T cells (9, 10). A model of the TCR–SAG–
MHC complex constructed from the crystal structures of
the TCR-
 
b
 
–SEC3 complex (6), of a TCR V
 
a
 
 domain
(11), and of the complex between staphylococcal entero-
toxin B (SEB) and an MHC class II molecule (12) suggests
that the SAG acts like a wedge between the TCR and
MHC molecules to displace the antigenic peptide away
from the TCR combining site. In this way, the SAG cir-
cumvents the normal mechanism for T cell activation by
recognition of specific peptide–MHC complexes (6).
To investigate the relationship between the affinity of
SAGs for TCR and MHC and their ability to activate T
cells, we have measured the binding of a set of SEC3 and
SEB mutants to soluble recombinant 14.3.d 
 
b
 
 chain and to
a human MHC class II molecule, HLA-DR1, loaded with
influenza virus hemagglutinin peptide 306–318 (HA 306–
318). These mutants were generated by alanine-scanning
mutagenesis of all SEC3 residues in contact to the TCR 
 
b
 
chain in the 
 
b
 
-SEC3 crystal structure, or by mutating se-
lected TCR-contacting residues of SEB (which is structur-
ally similar to SEC3 but binds the TCR more weakly) to
those of SEC3. We show that there is a direct correlation
between affinity and mitogenic potency, with SAGs that
have the highest affinity for the TCR 
 
b
 
 chain being the
most biologically active. We also show that a relatively
small increase in the affinity of the SAG–MHC interaction
is able to compensate a large decrease in SAG–TCR affin-
ity. Finally, a comparison of the so-called “functional
epitope” of SEC3 (those residues that contribute most to
TCR binding) with the “structural epitope” (all SEC3 res-
idues contacting the 
 
b
 
 chain in the crystal structure) en-
ables us to explain the ability of different SAGs to recog-
nize the same V
 
b
 
 elements.
 
Materials and Methods
 
Reagents.
 
All chemicals were of analytical grade. Restriction
endonucleases and DNA modifying enzymes were purchased
from New England Biolabs, Inc. (Beverly, MA). Oligonucle-
otides were obtained from Integrated DNA Technologies (Cor-
alville, IA). Radiolabeled [
 
35
 
S]dATP was from Amersham Corp.
(Arlington Heights, IL).
 
Production of Recombinant TCR 
 
b
 
 Chain.
 
Unglycosylated 14.3.d
V
 
b
 
C
 
b
 
 chain was obtained by elimination of four out of five po-
tential N-linked glycosylation sites through site-directed mu-
tagenesis and introduction of a termination codon at the end of
the first C region exon of the 
 
b
 
 chain (13). Asparagines at posi-
tions 24, 74, and 121 were mutated to glutamine, while the gly-
cosylation site at position 236 was eliminated by mutation of
Ser238 to valine. The 14.3.d 
 
b
 
 chain was produced in J558L cells
and affinity purified using the anti–mouse C
 
b
 
 monoclonal anti-
body H57-597 (13, 14). The unmutated N-linked glycosylation
site at position C
 
b
 
 186 was used in 
 
,
 
10% of the chains, as judged
by SDS-PAGE. The recombinant 
 
b
 
 chain was further purified by
gel filtration on a Superdex 75 fast protein liquid chromatography
column (Pharmacia Biotech AB, Uppsala, Sweden) before sedi-
mentation equilibrium or BIAcore experiments to eliminate aggre-
gated material that could interfere with affinity measurements (15).
 
Mutagenesis and Production of SEC3 and SEB Mutants.
 
The gene
for SEB, 
 
seb
 
, was obtained from C. Jones and S. Khan (University
of Pittsburgh School of Medicine, Pittsburgh, PA; reference 16).
Cloning and sequencing of the 
 
sec
 
 gene encoding SEC3 from 
 
Staph-
ylococcal aureus
 
 strain FRI913 was reported previously by Hovde
et al. (17). All SEB mutants and certain SEC3 mutants were pro-
duced by site-directed mutagenesis using a Muta-Gene M13 In
Vitro Mutagenesis Kit (Bio-Rad, Richmond, CA). The correspond-
ing genes, on a BamHI/HindIII fragment in the case of SEC3 and
on a KpnI/HindIII fragment in the case of SEB, were subcloned
into M13mp18. Mutagenic oligonucleotides were designed to re-
place wild-type codons with ones for alanine in the SEC3 gene or
with codons for threonine, tyrosine, or valine in the SEB gene.
The mutations were confirmed by DNA sequencing using a Se-
quenase Version 2.0 Kit (USB, Cleveland, OH). Mutated SEC3
genes were cloned into the expression vector pMIN164 (17) and
mutated SEB genes into pUC18. The enterotoxins were ex-
pressed in BL21(DE3) 
 
Escherichia coli
 
 cells, and the periplasmic
fraction, in which the SAGs are mostly contained, was obtained
by osmotic shock as previously described (18). After dialysis
against 20 mM Tris-HCl, pH 7.5, the periplasmic extract was ap-
plied to a RedA-Dye column (Amicon, Beverly, MA) as previ-
ously described (19). Bound proteins were eluted using a linear
0–500 mM NaCl gradient. The SAG-containing fractions were
pooled and concentrated. Alternatively, SEC3 mutants were pro-
duced by subcloning the gene for SEC3 on a BamHI/HindIII
fragment into pALTER. Oligonucleotide site-directed mutagen-
esis was accomplished using the Altered Sites In Vitro Mutagene-
sis Systems Kit (Promega, Madison, WI). Mutations were con-
firmed by sequencing as above. The mutated genes were cloned
into pMIN164 (17) for expression in 
 
E. coli
 
 DH5
 
a
 
 or 
 
S. aureus
 
RN 9220. The SAGs were initially purified from stationary phase
cultures by ethanol precipitation and preparative thin layer iso-
electric focusing was as previously described (1). All SEC3 and
SEB mutants were further purified on a MonoQ ion exchange
column (Pharmacia Biotech AB) before binding and activation
studies.
 
Production of Recombinant Peptide–HLA-DR1 Complex.
 
The
pACDR1 virus encoding both soluble DR
 
a
 
 and DR
 
b
 
1
 
*
 
0101
chains was provided to R.-P. Sékaly by Dr. L. Stern (Massachu-
setts Institute of Technology, Boston, MA). The virus was ampli-
fied and cloned by plaque assay using procedures described by
Summers and Smith (20). 
 
Spodoptera frugiperda
 
 (Sf21) cells (ob-
tained from Dr. C. Richardson, Ontario Cancer Institute, On-
tario, Canada) were grown in 
 
m
 
-carrier spinner flasks (Bellco
Technology, Vineland, NJ) in Grace’s medium (GIBCO BRL,
Gaithersburg, MD) supplemented with 10% fetal calf serum,
1.66% mass/vol lactalbumin hydrolysate, 1.66% mass/vol Yeasto-
late, and 1% pluronic acid (all from GIBCO BRL). Sf21 cells 
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(3–5 
 
3
 
 10
 
5
 
/ml) were infected with a stock of recombinant bacu-
lovirus encoding DR
 
a
 
/DR
 
b
 
1
 
*
 
0101 at a multiplicity of infection
of 5–10 PFU/cell and grown at 26
 
8
 
C for 12 h. The infected cells
were collected and returned to culture in an equal volume of
Grace’s medium containing 1% pluronic acid for 72 h after infec-
tion. The supernatant was collected and filtered, and protease in-
hibitors (0.1 
 
m
 
M pepstatin A, 0.5 mM phenylmethylsulfonylfluo-
ride, 2.5 mM EDTA) and 0.02% mass/vol NaN
 
3
 
 were added.
The DR 
 
ab
 
 dimer was purified by affinity chromatography ac-
cording to a slight modification of a protocol used by Stern and
Wiley (21). In brief, Sf21 supernatants were passed over a Sepharose
column coupled with L243 anti-DR monoclonal antibody. After
loading, the column was extensively washed with PBS. The MHC
protein was eluted using 50 mM 3-[cyclohexylamino]-1-pro-
panesulfonic acid, pH 11.5, and was immediately neutralized in
20% (vol/vol) 0.5 M Tris-HCl, pH 7.0. The empty 
 
ab
 
 DR1
dimer was loaded with the antigenic HA 306–318 peptide as pre-
viously described (21). A solution of 1.0 
 
m
 
M HLA-DR1 was in-
cubated in PBS containing protease inhibitors (0.1 mM aminoeth-
ylbenzenesulfonylfluoride, 4 
 
m
 
g/ml E-64, and 1 mM EDTA; all
from Boehringer Mannheim, Indianapolis, IN) and 0.02% NaN
 
3
 
in the presence of 10 
 
m
 
M HA 306–318 peptide (Tana Laborato-
ries, Houston, TX). The mixture was incubated for 3 d at 37
 
8
 
C
and HA306-318/HLA-DR1 complex was concentrated and pu-
rified on a Sephadex G75 (Pharmacia Biotech AB) gel filtration
column.
 
Sedimentation Equilibrium.
 
Equilibrium measurements of the
interactions between the TCR-
 
b
 
 chain and the various SAG mu-
tants, as well as between HLA-DR1 and SAGs, were carried out
with a Beckman XL-A Optima analytical ultracentrifuge using a
four-hole, An 55 rotor. The samples were prepared by dialysis
against 50 mM Tris-HCl, pH 7.5, at concentrations of the 1:1
complexes ranging from 4 to 10 
 
m
 
M. The experiments were per-
formed at 25
 
8
 
C at rotor speeds between 20,000 and 24,000 rpm.
The molar extinction coefficients used were: 43.2 mM
 
2
 
1
 
cm
 
2
 
1
 
 for
the TCR-
 
b
 
 chain; 34.2 mM
 
2
 
1
 
cm
 
2
 
1
 
 for SEC3 and SEC3 mutants;
39.6 mM
 
2
 
1
 
cm
 
2
 
1
 
 for SEB and SEB mutants; and 50.0 mM
 
2
 
1cm21
for HLA-DR1. The concentration distributions of the samples at
sedimentation equilibrium were acquired by an average of 25
measurements of absorbance at each radial position, with a nominal
spacing of 0.001 cm between each radial position. The data ob-
tained were analyzed as described by Malchiodi et al. (15). Errors
on the dissociation constants (Kds) were ,25% of parameter values.
BIAcore Analysis. The binding of the TCR-b chain to im-
mobilized enterotoxins was monitored with a BIAcore instru-
ment (Pharmacia Biosensor, Piscataway, NJ). The SAG mutants
were coupled to the dextran matrix of CM5 sensor chips using
the Amine Coupling Kit (Pharmacia Biosensor). All SEC3 or SEB
mutants, whose concentration were z100 mg/ml, were dialyzed
against 10 mM sodium acetate, pH 5.3, before coupling. The ac-
tivation and immobilization periods ranged from 5 to 7 min,
which yielded between 2,000 and 3,500 resonance units (RU) of
coupled SAG. The 14.3.d b chain was dialyzed against Hepes-
buffered saline (HBS) containing 150 mM NaCl, 10 mM Na-
Hepes, pH 7.5, 3.4 mM EDTA, and 0.005% Surfactant P20
(Pharmacia Biosensor). Twofold dilutions were made in the same
buffer. The measurements were carried out at 258C at a flow rate
of 5 ml/min over a period of 6 min. Dissociation was done with
HBS and the chip surface was regenerated by a pulse of 10 mM
HCl. The data were analyzed using the BIAevaluation 2.1 soft-
ware package (Pharmacia Biosensor); Kds were determined under
equilibrium binding conditions using Scatchard plots as previ-
ously described in (15, 22).
T Cell Proliferation Assay. 4 3 104 lymph node T cells from
RAG-22/2 TCR transgenic mice expressing the 14.3.d TCR
(23) were cultured together with 2 3 105 irradiated (10,000 rad)
BALB/c spleen cells as APCs in the presence of varying amounts
of different SAGs in 200 ml of IMDM supplemented with 10%
FCS as duplicates in flat-bottomed 96-well plates. After 48 or 96
h of incubation at 378C, 1 mCi/well of [3H]thymidine was added
for the next 12 h. Incorporation of radioactivity was then mea-
sured using a Betaplate 1250 system (Wallacy, Turku, Finland).
Results
Mutation of SEC3 Residues N23, Y90, and Q210 Has the
Most Effect on Binding to the TCR b Chain Whereas Mutations
in the 93-110 Disulfide Loop Have the Least. The functional
contribution of individual SEC3 residues to stabilization of
the complex with the 14.3.d b chain was determined by
alanine-scanning mutagenesis of all SEC3 residues in con-
tact to the b chain in the crystal structure (6). Alanine was
chosen because it eliminates the side chain without altering
the main-chain conformation and does not impose any ex-
treme steric or electrostatic effects (24). All affinity mea-
surements were performed using an engineered, unglyco-
sylated version of the 14.3.d b chain because of its stability
and monodisperse behavior in solution. In addition, earlier
studies had shown that this mutant b chain binds to a vari-
ety of SAGs with the same Kd as the associated ab TCR
heterodimer, or as the glycosylated b chain alone (15).
Binding affinities were determined by sedimentation
equilibrium, a technique with which even weak interac-
tions can be analyzed in solution. Before measuring com-
plex formation between SAGs and the TCR-b chain, the
behavior of the individual proteins was assessed by separate
runs. All species behaved well under the conditions used,
with no tendency to aggregate. The calculated molecular
weights for the b chain and the enterotoxins deviated ,8%
from the expected values based on amino acid composi-
tion. To assure the accuracy of our results, we measured b
chain–SAG interactions at two different rotor speeds and/
or protein concentrations. The affinity values obtained un-
der these different conditions differed by 30% at most. The
Kds for the interaction of the 14.3.d b chain with a panel of
SEC3 alanine mutants are listed in Table 1, and a represen-
tative sedimentation profile is shown in Fig. 1. As can be
seen, the affinities of the various SEC3 mutants for the b
chain vary between 3 and 150 mM, with all mutants bind-
ing similarly to, or weaker than, the wild-type SAG. Muta-
tion to alanine of three residues (G102, K103, and G106)
within the flexible 93–110 disulfide loop of SEC3 had no
or little effect on binding to the b chain. In contrast, SEC3
mutants N23A, Y90A, and Q210A bind the b chain at
least 50–100-fold less tightly than does the wild-type. At
the protein concentrations used (4–10 mM), the Kds of all
three mutants could be only estimated as z150 mM, but
the actual values may be significantly greater. Trials using
higher protein concentrations (up to 50 mM) in order to
favor complex formation were unsuccessful due to nonspe-
cific aggregation of the proteins. Mutagenesis of other826 Superantigen Binding to TCR-b Chain and MHC
SEC3 residues in contact with b chain (T20, Y26, N60,
V91, and F176) resulted in smaller decreases in affinity,
with  Kds ranging from 25 to 120 mM.
The Affinity of SEB for the TCR-b Chain Can Be Increased
by Grafting Residues from the TCR Binding Site of SEC3.
We also attempted to obtain mutants of SEC3 and SEB
with higher affinity for the 14.3.d b chain in order to see
whether such tighter binding mutants would also show in-
creased ability to stimulate T cells. In the case of the weakly
binding SEB (Kd 5 120 mM by sedimentation equilibrium;
Table 1) our approach was to graft residues from the TCR-
binding site of SEC3 (Kd 5 4.5 mM), which differ between
Table 1. Dissociation Constants for the Binding of Staphylococcal Enterotoxin Mutants to the TCR 14.3.d b Chain and Stimulatory
Activity of these Mutants
SAG mutant Kd analytical centrifuge Kd BIAcore DDG Stimulatory capacity
3 1026 M 3 1026 M kcal/mol ng/ml
SEC3 wild-type 4.5 3.0 200
SEC3 T20A 42 49 1.4 4,000
SEC3 N23A >150* NB .2.5 .30,000§
SEC3 Y26A 86 60 1.7 3,000
SEC3 N60A 25 48 1.3 2,000
SEC3 Y90A >150* 240 .2.5 9,000
SEC3 V91A 117 130 2.1 6,000
SEC3 G102A 4.6 ND 0.1 400
SEC3 K103A 5.6 9.4 0.4 1,000
SEC3 G106A 3.4 ND 0.1 400
SEC3 F176A 92 110 1.9 30,000
SEC3 Q210A >150* NB .2.5 .30,000§
SEB wild-type 120 140‡ 20
SEB L20T 100 120 30
SEB V26Y 26 12 5
SEB Y91V 140 160 100
SEB L20T, V26Y, Y91V >150 NB 7,000
Affinity measurements by sedimentation equilibrium and BIAcore, as well as the biological activity assays, were performed as described in Materials
and Methods. Differences in free energy changes are calculated as the differences between DGs of mutant and wild-type SAGs (DDG 5 DGmutant 2
DGwild-type). The values of the individual DGs are calculated from the average Kds obtained from sedimentation equilibrium and BIAcore measure-
ments according to the equation DG 5 2RT ln (1/Kd), where R is the universal gas constant and T is the absolute temperature in Kelvin. For the
three weakest binding mutants, N23A, Y90A, and Q210, a DDG value of .2.5 kcal/mol (which corresponds to a 70-fold decrease in affinity) is es-
timated, as these mutants bind at least 50–100-fold weaker than wild-type SEC3. The stimulatory capacity of different SAGs was estimated from the
dose (ng/ml) required to induce proliferation 100-fold above background. Background cpm were typically less than 100. NB, no detectable binding
observed in the BIAcore measurements at TCR-b chain concentrations up to 128 mM; ND, not determined.
*150 mM should be considered as a lower limit for these mutants.
‡Value for SEB wild-type was taken from the earlier work by Malchiodi et al. (15).
§For these SEC3 mutants, SAG concentrations of 30,000 ng/ml were not sufficient to induce proliferation 100-fold above background.
Figure 1. Sedimentation equilibrium profile of an equimolar mixture
of the 14.3.d TCR-b chain with SEC3 F176A. Sedimentation was per-
formed at 22,000 rpm in 50 mM Tris-HCl, pH 7.5, at 258C and a starting
concentration of 7.5 mM. (Bottom) Absorbance at 280 nm versus distance
from the rotation center in centimeters. (Top) The residuals (A280-nm, the-
oretical 2 A280-nm, observed) for the equilibrium between the two com-
ponents, yielding a Kd of 92 mM, are small and random. Similar results
were obtained for the other SEC3 and SEB mutants.827 Leder et al.
the two SAGs. As SEB and SEC3 have very similar three-
dimensional structures (25, 26) and bind the 14.3.d b chain
in essentially the same orientation (reference 6, Li and Mar-
iuzza, unpublished results), engineering such chimeric SEB
molecules was expected to be straightforward. Excluding
the flexible 93–110 disulfide loop of SEC3 (which, as dem-
onstrated above, does not functionally contribute to bind-
ing the b chain), the TCR binding sites of SEC3 and SEB
differ only at positions 20, 26, and 91. We therefore re-
placed SEB residues L20, V26, and Y91 with SEC3 resi-
dues T20, Y26, and V91. We constructed three single mu-
tants (SEB L20T, V26Y, and Y91V) in which these
residues were individually substituted, as well as a triple
mutant in which all three SEC3 residues were grafted onto
the TCR binding site of SEB. As can be seen in Table 1,
only SEB V26Y showed improved affinity: its Kd (as deter-
mined by sedimentation equilibrium) was 26 mM, approxi-
mately five times lower than that of wild-type SEB, but still
six times higher than that of SEC3. Surprisingly, mutations
L20T and Y91V did not significantly alter the affinity of
SEB for the b chain, whereas no binding whatsoever could
be detected in the case of the the triple mutant.
We also attempted to design mutants of SEC3 with en-
hanced affinity for the 14.3.d b chain on the basis of the
crystal structure of the b–SEC3 complex. For instance,
SEC3 residues Y26 and Y90 were replaced by tryptophan
and V91 by isoleucine with the expectation that the larger
side chains of these residues would make additional van der
Waals contacts with the b chain and contribute to hydro-
phobic stabilization of the complex. In addition, SEC3 res-
idue G19 was mutated to lysine and F176 to glutamic acid,
since the crystal structure suggested that charged amino ac-
ids at these positions could form salt bridges with residues
of opposite charge on the TCR b chain. However, these
mutants either bound the b chain with the same Kd as
wild-type SEC3 (Y26W or V91I), or even displayed up to
10-fold weaker affinities (G19K, Y90W, and F176E; data
not shown).
The Dissociation Constants from Sedimentation Equilibrium
Are Confirmed by Surface Plasmon Resonance (BIAcore) Measure-
ments. We coupled most of the SEC3 and SEB mutants
described above directly to the dextran matrix of sensor
chips through the primary amino groups of the proteins.
Unglycosylated 14.3.d b chain in increasing concentrations
(1–128  mM) was injected and concentration-dependent
surface plasmon resonance profiles such as those shown in
Fig. 2 for SEC3 N60A (panel A) and SEB V26Y (panel B)
were recorded. As in the case of the wild-type proteins, the
binding of all SEC3 and SEB mutants tested was character-
ized by very fast on- and off-rates. In fact, these kinetic
rates were too fast to accurately measure, although the asso-
ciation and dissociation rate constants may be estimated at
.105 M21s21 and .0.1 s21, respectively. Therefore, affini-
ties were determined under equilibrium binding condi-
tions, in which we took report points for Scatchard analysis
20–40 s after injection. Scatchard plots for SEC3 N60A and
SEB V26Y, after correction for nonspecific binding, are
shown in Fig. 2, C and D. The plots are linear, with corre-
lation coefficients of 0.99; Kds were calculated directly
from the slopes. The predicted maximum specific binding,
calculated from the x-intercept assuming a linear relation-
ship between mass of bound protein and measured RU
(27), indicated that nearly 90% of immobilized SAG mole-
cules retained their binding activity. Similar results were
observed for the other mutants tested; Table 1 lists the Kd
values measured by BIAcore. Comparison of the affinities
obtained by sedimentation equilibrium and BIAcore
showed reasonable agreement, with values for Kd differing
by not more than a factor of two. These variations are
probably attributable to intrinsic differences between the
two methods. In the sedimentation equilibrium both bind-
ing partners are in solution, whereas in BIAcore one of the
ligands is chemically coupled to a solid support, which may
result in small changes in the conformation and/or accessi-
bility of the immobilized molecule. However, we do not
observe any systematic difference between these two very
different physical methods. In some cases, the affinities ob-
tained from BIAcore were lower (SEC3 T20A, N60A, and
K103A) than those from sedimentation equilibrium, whereas
in others the reverse was true (SEC3 wild-type, Y26A, and
SEB V26Y). Further, we found that both methods gave
very reproducible results, with Kd values deviating by not
Figure 2. Binding of 14.3.d. b chain to immobilized SEC3 N60A or
SEB V26Y. The b chain was injected at eight different concentrations
ranging from 1 to 128 mM over surfaces coupled with (A) SEC3 N60A
(2,700 RU) or (B) SEB V26Y (3,600 RU). Buffer flow rates were 5 ml/
min and the equilibrium was typically reached within 10 s. Scatchard
analysis of the binding of the b chain to SEC3 N60A (C) with data de-
rived from A after correction for nonspecific binding, and of the binding
of the b chain to SEB V26Y (D) with data derived from (B), yielded lin-
ear plots with correlation coefficients of 0.99 in both cases. The apparent
Kds for the b chain–SEC3 N60A and the b chain–SEB V26Y reactions
were 42 and 12 mM, respectively. Similar binding profiles and Scatchard
plots were obtained with the others SEC3 and SEB mutants.828 Superantigen Binding to TCR-b Chain and MHC
more than 30% in each case. We therefore believe that
these two methods combined give an accurate picture of
the functional importance of individual SEC3 or SEB con-
tact residues in complex formation with the TCR-b chain.
The Biological Activity of SEC3 and SEB Mutants Correlates
with their Affinity for the TCR-b chain. To mimic normal
physiological conditions as closely as possible, we used rest-
ing lymph node T cells bearing the 14.3.d TCR from
RAG-22/2 TCR transgenic mice (23) to measure the
stimulatory effects of different SAGs on BALB/c spleen
cells expressing I-Ed (Fig. 3). The results are summarized in
Table 1 as the dose of each SAG required to induce T cell
proliferation 100-fold above background. Dose-response
curves for most of the mutant SAGs did not reach a pla-
teau, even at the highest SAG concentrations tested (Fig.
3). Thus, it is very difficult to estimate either the maximal
stimulatory capacity (total proliferation in the assays), or the
concentration of SAG that is required to obtain 50% of the
maximal effect. Nevertheless, we believe that our defini-
tion of the stimulatory capacity gives an accurate picture of
the relative biological activities of the different SEB and
SEC3 mutants. A comparison with the results from the
binding experiments reveals a direct correlation between
the affinity and the biological activity of SEC3 and SEB
mutants: the higher the affinity of a particular mutant for
the TCR-b chain, the greater its mitogenic potency. For
instance, SEC3 mutants G102A, K103A, and G106A, all
located on the flexible disulfide loop of this SAG, bind to
the b chain with Kds similar to that of wild-type SEC3 and
also show similar biological activity. On the other hand,
SEC3 mutants N23A and Q210A, with Kds >150 mM, ex-
hibit no measurable stimulatory effects whatsoever. How-
ever, another very low-affinity mutant, SEC3 Y90A, is still
able to activate T cells, although z50-fold higher concen-
trations are needed to achieve the same effect as with wild-
type. This difference between no apparent biological activ-
ity and low biological activity is reflected in the results
from BIAcore measurements, in which SEC3 Y90A
yielded a Kd of 240 mM, whereas SEC3 N23A and Q210A
did not show any detectable binding (Table 1). Except for
F176A, the mutants that have intermediate affinities (i.e.,
SEC3 T20A, Y26A, N60A, V91A) consistently stimulated
T cells transgenic for the 14.3.d TCR less efficiently than
wild-type SEC3, but significantly better than the three mu-
tants with the weakest binding. A very similar picture
emerged from experiments with the various SEB mutants:
SEB V26Y, with its increased affinity, also exhibited a
slightly enhanced mitogenic potency compared to wild-
type SEB, whereas the triple mutant, with no detectable
binding to the 14.3.d b chain, only barely stimulated T
cells. However, an apparent exception to this simple affin-
ity-activity rule was the finding that SEB stimulated trans-
genic T cells z10-fold better than SEC3, even though the
affinity of SEB for the TCR-b chain is z35-fold lower
than that of SEC3 (Table 1). This effect was observed using
either BALB/c spleen cells or MHC class II-negative
mouse fibroblasts expressing HLA-DR1 as APCs (data not
shown).
SEB Binds HLA-DR1 More Tightly than SEC3. To de-
termine whether the surprisingly strong mitogenic potency
of SEB relative to SEC3 could be attributed to tighter
binding to MHC class II on APCs, we examined the bind-
ing of SEB and SEC3 to soluble recombinant I-Ed loaded
with HA 110–120 (28), as well as to HLA-DR1 loaded
with HA 306–318. Both peptide–MHC class II complexes
behaved well in separate sedimentation equilibrium runs,
which yielded apparent molecular weights of 49 kD for I-Ed
and 50 kD for DR1, in close agreement with expected val-
ues (52 kD for both I-Ed and DR1). However, we could
not detect any binding of I-Ed to either SEB or SEC3, in
agreement with BIAcore experiments reported by Kozono
et al. using I-Ek (29). In contrast, we could easily measure a
Kd of 14 mM for the interaction of SEB with HLA-DR1
and a corresponding value of 48 mM for SEC3. This is also
consistent with the observation that DR1 is a much more
efficient presenting element for SEB and SEC3 than I-E in
Figure 3. Functional characterization of mutant SAGs. The mitogenic
potencies of wild-type SEC3 and SEC3 mutants are shown in A and of
wild-type SEB and SEB mutants in B. Proliferation of lymph node T cells
from RAG-22/2 TCR transgenic mice was measured using irradiated
BALB/c spleen cells in the presence of various SAGs. The SAG concen-
trations used are indicated with the different symbols. Proliferation results
at 72 h are shown here. The results were qualitatively the same at 24 h.829 Leder et al.
T cell stimulation assays (30). Therefore, the unexpectedly
high mitogenic potency of SEB relative to SEC3 could be
at least partially explained by the tighter binding of SEB to
MHC class II. This observation is supported by earlier
studies that also suggested a correlation between affinity
and biological activity, since SAGs with weaker binding to
MHC also showed decreased mitogenic potency (31, 32).
We also determined the affinities of two SEC3 mutants,
G102A and V91A, for HLA-DR1. SEC3 G102A had the
same affinity for the 14.3.d b chain as the wild-type SAG,
whereas the affinity of SEC3 V91A was decreased by z30-
fold. In contrast, both mutants bound to HLA-DR1 with
similar affinities (Kd 5 54 mM for V91A and Kd 5 59 mM
for G102A), and about equally as well as wild-type SEC3.
These results demonstrate that mutations in at least these
particular TCR-contacting residues of SEC3 have no influ-
ence on affinity for MHC, in agreement with the finding
that the corresponding residues of SEB are not in contact
with MHC in the crystal structure of the SEB–DR1 com-
plex (12).
Discussion
While the crystal structure of the 14.3.d b chain–SEC3
complex (6) provides detailed information on the molecu-
lar architecture of the TCR–SAG interface, it does not tell
us what the actual functional contribution of individual res-
idues to complex stabilization is. To answer this question,
SEC3 residues in contact with the b chain were subjected
to alanine-scanning mutagenesis (24) in order to analyze
their relative importance to binding. The free energy of
binding was calculated from the equation DG 5 2RT ln
(1/Kd), where R is the univeral gas constant and T is the
absolute temperature. In this way, we constructed a “ther-
modynamic map” of the TCR binding site of SEC3 that
shows the relative loss of binding-free energy for individual
alanine mutants compared to wild-type SEC3 (DDG 5
DGmutant 2 DGwild-type). As shown in Table 1, the most de-
stabilizing alanine substitutions are located at positions
N23, Y90, and Q210 with a DDG >2.5 kcal/mol. Signifi-
cant contributions (1.3 to 2.1 kcal/mol) can also be ob-
served for contact residues T20, Y26, N60, V91, and F176.
In contrast, replacement of G102, K103, and G106 by ala-
nine has little or no effect (,0.5 kcal/mol). In agreement
with this result, these four interface residues form part of
the 93–110 disulfide loop of SEC3 that was only poorly
visible in the crystal structure of the b–SEC3 complex,
suggesting high intrinsic mobility (6). Therefore, 8 out of
11 SEC3 contact residues are energetically important in
binding the TCR-b chain such that stabilization of the
b–SEC3 complex is achieved by the accumulation of many
productive interactions of varying strength over a large
portion of the interface with the TCR. This finding that a
majority of contact residues significantly contribute to
binding is similar to the case of an anti–hen eggwhite
lysozyme antibody binding to an antiidiotypic antibody (22),
but different from the binding of human growth hormone
to its receptor, where only a few contact residues appear to
be responsible for the formation of a stable complex (33).
Fig. 4 shows the functional epitope of SEC3 involved in
complex formation with the 14.3.d b chain mapped onto
its three-dimensional structure. With the exception of
F176, which lies at the periphery, the most energetically
important SEC3 residues (N23, Y26, Y90, V91, and
Q210) are clustered at the center of the cleft between the
small and large domains of the enterotoxin molecule. All
five of these SEC3 residues interact with a continuous
stretch of amino acids (residues 50–55) in the CDR2 loop
of the Vb domain. Hydrophilic residues N23 and Q210
form hydrogen bonds with backbone atoms of this part of
CDR2, whereas hydrophobic residues Y26, Y90, and V91
make a number of van der Waals contacts with main chain
and side chain atoms in the CDR2 loop (6). The finding
that mutations in the highly mobile 93–110 disulfide loop
of SEC3 have little or no effect on binding affinity is in
agreement with the high sequence variability in this region
present in SEC1-3, SEB, and streptococcal pyrogenic exo-
toxin A (SPEA) (Fig. 5), all of which bind the 14.3.d b
chain and activate Vb8.2-bearing T cells (15). On the
other hand, “hot spot” residues making the greatest ener-
getic contribution to stabilization of the b–SEC3 complex
(N23, Y90, and Q210), as well as the less important N60,
are strictly conserved in SEC1-3, SEB, and SPEA. Even in
SAGs such as SEA, SED, and SEE, which do not recognize
Vb8.2, position 23 is also occupied by an asparagine; this
residue has proven critical for T cell stimulation in earlier
mutagenesis experiments (32). These observations empha-
size the functional importance of each of the conserved in-
terface residues, and makes it understandable why SAGs
having other residues at these positions show different Vb-
binding specificities. 
The results obtained with the SEB–SEC chimeras were
quite surprising, because only SEB mutant V26Y had a
higher affinity (Kd 5 19 mM, taken as an average of sedi-
mentation equilibrium and BIAcore measurements) than
wild-type SEB (Kd 5 130 mM). The two other SEB single
mutants, L20T and Y91V, did not show improved binding
and the triple mutant did not show any detectable binding
to the 14.3.d b chain. Since alanine-scanning mutagenesis
of SEC3 implicated Y26 as functionally important, it is rea-
sonable that replacement of the valine that is present in
wild-type SEB by the bulkier tyrosine should increase the
number of van der Waals contacts to the b chain and hence
improve the affinity of that mutant. Other studies also re-
vealed a key role of residue 26 in SEC 1-3 and SEB in the
specificity of these SAGs for different human TCRs. Thus,
SEB and SEC1 react strongly with human Vb3 but not
with Vb13.1, whereas SEC3 and SEC2 bind well to
Vb13.1 but only weakly with Vb3 (8). Site-directed mu-
tagenesis has shown that these reactivity differences can be
fully attributed to the amino acid at position 26, which is
valine in SEB and SEC1 but tyrosine in SEC2 and SEC3.
However, it is quite puzzling that the SEB single mutant
Y91V and the SEB triple mutant, with an almost com-
pletely grafted SEC3 binding site, react with the 14.3.d b830 Superantigen Binding to TCR-b Chain and MHC
chain only very weakly, or not at all. This behavior could
be explained by unanticipated conformational changes in
SEB induced by these mutations, or by subtle structural dif-
ferences between the b–SEB and b–SEC3 complexes that
are not apparent at the current resolution of the x ray struc-
tures (z3.5 Å). For instance, small differences in the rela-
tive orientation of SAG and TCR in the two complexes
may lead to unanticipated effects on binding when inter-
face residues are mutated. Furthermore, attempts to ratio-
nally design better-binding SEC3 mutants (e.g., G19K,
Y26W, Y90W, V91I, and F176E) were unsuccessful, since
in all cases the affinity was the same as that of wild-type
SEC3, or even up to 10-fold lower. It is therefore entirely
possible that the TCR binding site of SEC3 is already opti-
mized and that the introduction of charged (G19K, F176E)
or bulkier (Y90W) residues leads to less favorable interac-
tions and a consequent decrease in affinity.
Our comparison between affinity and biological activity
clearly shows that SAG mutants that bind the TCR-b
chain more tightly stimulate T cells more efficiently than
Figure 4. Space-filling model of the surface of SEC3 in contact with the 14.3.d TCR-b chain in the crystal structure. Residues are color coded according to
the loss of binding free energy (DDG) upon alanine substitution: red, .2.5 kcal/mol; yellow, 1.5-2.5 kcal/mol; green, 0.5-1.5 kcal/mol; blue, ,0.5 kcal/mol.
Figure 5. Sequence alignment of bacterial superantigens (SEC1-3,
SEB, SPEA, SEA, SED, and SEE). Residues of SEC3 in contact with the
TCR-b chain are boxed in colors according to the loss of binding-free
energy (DDG) upon alanine substitution. The color code is the same as
that used in Fig. 4. The homologous residues in the other SAGs are only
boxed in color if they are identical with those in SEC3. SEB residues
contacting MHC in the crystal structure of the SEB–HLA–DR1 complex
(12), and the corresponding residues of SEC3, are boxed in cyan if identi-
cal in SEB and SEC3 and in magenta if different.831 Leder et al.
do SAG mutants with lower affinities. This observation
complements recent studies of T cell activation by peptide–
MHC ligands, which strongly suggest that the affinity of
the TCR–peptide–MHC interaction plays a critical role in
determining the nature of the T cell response (34). For ex-
ample, it has been shown that peptide–MHC antagonists
that induce T cell anergy may act by binding the TCR
with affinities that are below those of peptide–MHC ago-
nists. Furthermore, the so-called “serial triggering” model
of T cell activation argues that the rather low affinities and
fast off-rates observed for many peptide–MHC–TCR in-
teractions are in fact necessary to enable a single peptide–
MHC complex to serially engage a large number of TCRs
(35, 36). Indeed, ligands with too high of an affinity for the
TCR are predicted to be actually less efficient at triggering
T cells. We have shown that, like peptide–MHC, the
binding of SAGs to the TCR is characterized by relatively
low affinities and fast dissociation rates. This suggests that
SAGs “mimic” the interaction of peptide–MHC com-
plexes with the TCR in terms of affinities and kinetics, a
conclusion also drawn by Viola and Lanzavecchia (36).
However, it remains to be established whether there is in-
deed an optimum affinity for T cell activation by SAGs,
such that SAG variants with either higher or lower affinities
than this optimum value exhibit decreased ability to stimu-
late T cells. Alternatively, mutant SAGs with progressively
higher affinities for the TCR relative to the wild-type
would stimulate T cells increasingly well, until some pla-
teau of maximum stimulation is reached. Unfortunately,
our current data do not permit us to distinguish between
the two possibilities since we were unable to engineer SAG
variants with markedly enhanced binding to the TCR-b
chain. In the best case, SEB V26Y bound to the b chain
only approximately sevenfold more tightly than did the
wild-type SAG.
The only notable discrepancy in the observed correlation
of activity with affinity is that SEB exhibited an z10-fold
higher potency than SEC3 in T cell stimulation assays,
even though its affinity for the TCR-b chain (Kd 5 130
mM) is much lower than that of SEC3 (Kd 5 3.8 mM).
Since the activation of T cells by SAGs requires simulta-
neous binding of the SAG to TCR and to MHC on the
APCs, this discrepancy could be reasonably explained by a
tighter binding of SEB than SEC3 to MHC molecules.
The crystal structure of the complex between HLA-DR1
and SEB (12) reveals that MHC-contacting residues of SEB
are different in SEC3 (Fig. 5). These sequence differences
may well result in different affinities of SEB and SEC3 for
MHC class II and thereby exert a significant effect on the
mitogenic potency of these SAGs. Indeed, we found that
SEB binds to HLA-DR1 with a Kd of 14 mM, whereas the
corresponding value for SEC3 was 48 mM. This threefold
higher affinity of SEB for MHC appears to compensate for
its 35-fold lower affinity for the TCR. However, it is
somewhat puzzling that this rather modest difference in
SAG–MHC affinity has such a large impact on biological
activity, especially given that the effects of changes in
TCR–SAG affinity on SAG activity are proportionately
much less pronounced (Table 1). One explanation may be
that the tighter binding of SEB to HLA-DR1 is mainly the
result of a slower off-rate leading to a considerably longer
residence time of SEB molecules on the MHC and there-
fore to much more efficient presentation of the SAG to the
T cell. Another could be that some minor structural differ-
ences between the trimolecular MHC–SEB–TCR and
MHC–SEC3–TCR complexes may result in altered bind-
ing properties that cannot be easily discerned by examining
either the MHC–SAG or TCR–SAG complexes individu-
ally. Another important question regarding T cell activa-
tion by SAGs remains as well: how can a SAG efficiently
cross-link the APC and T cell if its affinity for both MHC
and TCR is quite weak? This would appear to be less of an
issue for conventional T cell activation by peptide–MHC
complexes because only one low-affinity interaction is in-
volved. One possibility is that accessory molecules such as
CD4 help stabilize the TCR–SAG–MHC complex suffi-
ciently for activation to occur. Another is that the overall
stability of the MHC–SAG–TCR complex is greater than
one would expect from considering the TCR–SAG and
MHC–SAG interactions independently. In other words,
the binding of SAGs to TCR and MHC may be a cooper-
ative process such that the SAG–MHC complex binds the
TCR with a higher affinity than does SAG alone. Indeed,
surface plasmon resonance experiments have suggested a
tighter binding of an immobilized TCR to SEB complexed
with HLA-DR1 than to SEB alone (37). Furthermore, our
current model of the MHC–SAG–TCR complex (6) sug-
gests that the Va domain of the TCR can contact the
MHC b1 domain, perhaps helping to stabilize the overall
complex. However, only an actual crystal structure deter-
mination of an MHC–SAG–TCR complex, combined
with further binding experiments with all three compo-
nents, will reveal whether cooperative effects in the trimo-
lecular complex in fact occur, and if so, how exactly they
act to determine T cell stimulation by SAGs.
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